Projected effectiveness of HIV detection during early infection and rapid ART initiation among MSM and transgender women in Peru: A modeling study.
Antiretroviral therapy
HIV incidence
HIV prevention
Mathematical model
Journal
Infectious Disease Modelling
ISSN: 2468-0427
Titre abrégé: Infect Dis Model
Pays: China
ID NLM: 101692406
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
10
2018
revised:
01
04
2019
accepted:
03
04
2019
entrez:
27
4
2019
pubmed:
27
4
2019
medline:
27
4
2019
Statut:
epublish
Résumé
The We designed a transmission dynamic model to simulate the HIV epidemic among MSM and TW in Peru, calibrated to data on HIV prevalence and ART coverage from 2004 to 2011. We assessed the impact of an intervention starting in 2018 in which up to 50% of the new infections were diagnosed within three months of acquisition and initiated on ART within 1 month of diagnosis. We estimated the impact of the intervention over 20 years using the cumulative prevented fraction of new HIV infections compared to scenarios without intervention. Our model suggests that only 19% of the infected MSM and TW are virally suppressed in 2018 and 35%-40% of the new HIV infections are transmitted from contacts with acutely-infected partners. An intervention reaching 10% of Early detection of HIV infections and rapid initiation of ART among MSM is desirable as it would increase the effectiveness of the HIV prevention program in Peru. Targeting high-risk MSM and TW will be highly efficient.
Sections du résumé
BACKGROUND
BACKGROUND
The
METHODS
METHODS
We designed a transmission dynamic model to simulate the HIV epidemic among MSM and TW in Peru, calibrated to data on HIV prevalence and ART coverage from 2004 to 2011. We assessed the impact of an intervention starting in 2018 in which up to 50% of the new infections were diagnosed within three months of acquisition and initiated on ART within 1 month of diagnosis. We estimated the impact of the intervention over 20 years using the cumulative prevented fraction of new HIV infections compared to scenarios without intervention.
FINDINGS
RESULTS
Our model suggests that only 19% of the infected MSM and TW are virally suppressed in 2018 and 35%-40% of the new HIV infections are transmitted from contacts with acutely-infected partners. An intervention reaching 10% of
CONCLUSIONS
CONCLUSIONS
Early detection of HIV infections and rapid initiation of ART among MSM is desirable as it would increase the effectiveness of the HIV prevention program in Peru. Targeting high-risk MSM and TW will be highly efficient.
Identifiants
pubmed: 31025025
doi: 10.1016/j.idm.2019.04.001
pii: S2468-0427(18)30050-2
pmc: PMC6475714
doi:
Types de publication
Journal Article
Langues
eng
Pagination
73-82Subventions
Organisme : NIDA NIH HHS
ID : R01 DA032106
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
AIDS. 2002 Jun 14;16(9):1271-7
pubmed: 12045493
AIDS. 2003 Sep 5;17(13):1871-9
pubmed: 12960819
AIDS. 2004 Jun 18;18(9):1311-20
pubmed: 15362664
AIDS. 2005 Jan 3;19(1):85-90
pubmed: 15627037
J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):578-85
pubmed: 17279049
J Infect Dis. 2007 Apr 1;195(7):951-9
pubmed: 17330784
AIDS. 2007 Aug 20;21(13):1723-30
pubmed: 17690570
J Theor Biol. 2008 Sep 7;254(1):178-96
pubmed: 18572196
J Infect Dis. 2008 Sep 1;198(5):687-93
pubmed: 18662132
J Virol. 2009 Apr;83(7):3288-97
pubmed: 19129448
J Infect Dis. 2009 Feb 1;199(3):427-31
pubmed: 19133810
Sex Health. 2009 Mar;6(1):19-33
pubmed: 19254488
J Acquir Immune Defic Syndr. 2009 May 1;51 Suppl 1:S60-6
pubmed: 19384104
AIDS Behav. 2009 Dec;13(6):1054-60
pubmed: 19504178
Sex Transm Infect. 2010 Jun;86(3):163-8
pubmed: 19854700
AIDS. 2010 Mar 27;24(6):907-13
pubmed: 20139750
J Infect Dis. 2010 May 15;201(10):1488-97
pubmed: 20384495
Int J Epidemiol. 2010 Aug;39(4):1048-63
pubmed: 20406794
Curr Opin HIV AIDS. 2010 Jul;5(4):277-82
pubmed: 20543601
AIDS Behav. 2011 May;15(4):687-92
pubmed: 20890654
Retrovirology. 2011 Jul 07;8:54
pubmed: 21736738
AIDS Res Hum Retroviruses. 2012 May;28(5):460-4
pubmed: 21806486
J Theor Biol. 2011 Nov 7;288:9-20
pubmed: 21840324
J Infect Dis. 2011 Oct 1;204(7):1115-9
pubmed: 21881127
AIDS Behav. 2012 May;16(4):872-81
pubmed: 21983694
PLoS One. 2012;7(2):e31695
pubmed: 22348121
PLoS One. 2012;7(11):e50522
pubmed: 23209768
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):356-62
pubmed: 23242158
PLoS One. 2013;8(2):e55312
pubmed: 23457467
Int J STD AIDS. 2013 Jan;24(1):18-30
pubmed: 23512511
AIDS. 2013 Nov 28;27(18):2943-51
pubmed: 23939237
PLoS Med. 2013 Dec;10(12):e1001568; discussion e1001568
pubmed: 24339751
Science. 2014 Jul 11;345(6193):1254031
pubmed: 25013080
Lancet Glob Health. 2014 Jan;2(1):e23-34
pubmed: 25104632
J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):337-44
pubmed: 25469526
J Infect Dis. 2015 Jun 1;211(11):1757-60
pubmed: 25542958
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):444-51
pubmed: 26990823
Int J STD AIDS. 2016 Oct;27(12):1039-1048
pubmed: 27099168
Lancet HIV. 2016 Jul;3(7):e323-32
pubmed: 27365207
JAMA. 2016 Jul 12;316(2):171-81
pubmed: 27404185
AIDS. 2016 Nov 28;30(18):2875-2883
pubmed: 27662550
J Int AIDS Soc. 2017 Jun 28;20(1):21579
pubmed: 28691435
J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):350-357
pubmed: 29206720
Am J Epidemiol. 2018 Aug 1;187(8):1577-1585
pubmed: 29522079
Sci Rep. 2018 Apr 17;8(1):6066
pubmed: 29666455
Lancet HIV. 2018 Aug;5(8):e438-e447
pubmed: 30025681
Vaccine. 2019 Apr 10;37(16):2258-2267
pubmed: 30890385